[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol; 2010 Dec 10;28(35):5210-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
  • PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy.
  • We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines.
  • PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone.
  • RESULTS: This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III.
  • The International Union Against Cancer R0 resection rate was 81.9% after neoadjuvant chemotherapy as compared with 66.7% with surgery alone (P = .036).
  • The surgery-only group had more lymph node metastases than the neoadjuvant group (76.5% v 61.4%; P = .018).
  • Postoperative complications were more frequent in the neoadjuvant arm (27.1% v 16.2%; P = .09).
  • Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cardia / pathology. Cardia / surgery. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] JAMA. 2010 May 5;303(17):1729-37 [20442389.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):423-9 [12836016.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1248-52 [7552009.001]
  • [Cites] J Infus Chemother. 1996 Summer;6(3):123-6 [9229322.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2580-5 [17577037.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5062-7 [19770374.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):139-44 [10761793.001]
  • (PMID = 21060024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004099
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10-CA11488-29
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3020693
  •  go-up   go-down


2. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ: Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol; 2010 Feb 10;28(5):731-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.
  • (AMAROS) phase III study compares axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer patients with tumor-positive sentinel nodes.
  • In the ART arm, the extent of nodal involvement remains unknown, which could have implications on the administration of adjuvant therapy.
  • In this preliminary analysis, we studied the influence of random assignment to ALND or ART on the choice for adjuvant treatment.
  • PATIENTS AND METHODS In the first 2,000 patients enrolled in the AMAROS trial, we analyzed the administration of adjuvant systemic therapy.
  • Multivariate analysis was used to assess variables affecting the administration of adjuvant chemotherapy.
  • Adjuvant therapy was applied according to institutional guidelines.
  • Results Of 2,000 patients, 566 patients had a positive sentinel node and were treated per random assignment.
  • There was no significant difference in the administration of adjuvant systemic therapy.
  • In the ALND and ART arms, 58% (175 of 300) and 61% (162 of 266) of the patients, respectively, received chemotherapy.
  • Endocrine therapy was administered in 78% (235 of 300) of the patients in the ALND arm and in 76% (203 of 266) of the patients in the ART arm.
  • Treatment arm was not a significant factor in the decision, and no interactions between treatment arm and other factors were observed.
  • Multivariate analysis showed that age, tumor grade, multifocality, and size of the sentinel node metastasis significantly affected the administration of chemotherapy.
  • Within the ALND arm, the extent of nodal involvement remained not significant in a sensitivity multivariate analysis.
  • CONCLUSION Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have no major impact on the administration of adjuvant therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):980-91 [11181660.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):295-302 [18661261.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] N Engl J Med. 2002 Aug 22;347(8):567-75 [12192016.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):233-40 [13129630.001]
  • [Cites] Breast Cancer Res. 2004;6(4):165-9 [15217489.001]
  • [Cites] Ann Surg. 1968 Sep;168(3):337-56 [4970947.001]
  • [Cites] Cancer. 1971 Dec;28(6):1443-52 [5127794.001]
  • [Cites] Br J Surg. 1974 Oct;61(10):766-9 [4416583.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):170-4 [6988032.001]
  • [Cites] Lancet. 1980 Jul 12;2(8185):55-60 [6105244.001]
  • [Cites] Br J Surg. 1982 Dec;69(12):693-6 [7171967.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] N Engl J Med. 1997 Oct 2;337(14):949-55 [9395428.001]
  • [Cites] Cancer. 1998 Dec 15;83(12 Suppl American):2776-81 [9874397.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):109-16 [10030423.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1641-8 [10335782.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):116-26 [15657341.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2716-25 [15837986.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):599-609 [16670385.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92 [16954471.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):729-35 [18258980.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Feb;20(1):31-4 [18345543.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3530-5 [18640934.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 4;93(13):979-89 [11438563.001]
  • (PMID = 20038733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA011488-38
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2834391
  •  go-up   go-down


3. Maughan KL, Lutterbie MA, Ham PS: Treatment of breast cancer. Am Fam Physician; 2010 Jun 1;81(11):1339-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of breast cancer.
  • Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment.
  • This article reviews typical treatments based on stage, histology, and biomarkers.
  • Lobular carcinoma in situ does not require treatment.
  • Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy.
  • Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy.
  • Radiation therapy following breast-conserving surgery decreases mortality and recurrence.
  • Sentinel lymph node biopsy is considered for most breast cancers with clinically negative axillary lymph nodes, and it does not have the adverse effects of arm swelling and pain that are associated with axillary lymph node dissection.
  • Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status.
  • In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2).
  • Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery.
  • Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation.
  • Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Mastectomy. Neoplasm Staging. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1330-2 [20521750.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):507; author reply 507 [21391515.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):502-6; author reply 507 [21391514.001]
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1347-9 [20527363.001]
  • (PMID = 20521754.001).
  • [ISSN] 1532-0650
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


Advertisement
4. Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK: Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer; 2000 Dec 15;89(12):2521-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
  • BACKGROUND: This randomized controlled trial was to determine whether a combination chemotherapy regimen that contains anthracycline (doxorubicin and cyclophosphamide [AC]) is superior to the conventional cyclophosphamide, methotrexate, and 5-fluorouracil [CMF] combination in premenopausal women with axillary lymph node positive Stage II breast carcinoma.
  • METHODS: Premenopausal women with lymph node positive breast carcinoma were stratified according to age (younger than 35 or 35 years or older) and the number of positive axillary lymph nodes (1-3, 4-9, or >/= 10) and then randomly assigned to receive either doxorubicin 40 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenously (i.v.) every 3 weeks or cyclophosphamide 100 mg/m(2) orally on Days 1 through 14, methotrexate 40 mg/m(2) and 5-fluorouracil 500 mg/m(2) i.v. on Days 1 and 8 every 4 weeks.
  • Eighteen of the 55 AC patients developed recurrence compared with 16 of the 69 CMF patients.
  • The corresponding data for the CMF arm were 4%, 16%, and 3%, respectively.
  • More leukopenia (52%, mostly Grade 1-2) occurred in the CMF arm than in the AC arm (33%, P = 0.001), but no febrile episode was accompanied with leukopenia.
  • CONCLUSIONS: This study showed no difference between AC and CMF with respect to both disease free and overall survival rates in premenopausal women with axillary lymph node positive breast carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymph Nodes / drug effects
  • [MeSH-minor] Adult. Anemia / chemically induced. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Leukopenia / chemically induced. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Premenopause. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11135211.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJ, Richelt DJ, Rodenhuis S: Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol; 2002 May;13(5):689-98
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
  • BACKGROUND: The aim of this study was to present an update of overall (OS) and disease-free survival (DFS) and to evaluate the correlation between outcome and pathological findings at surgery in a randomized trial of high-dose chemotherapy following neoadjuvant chemotherapy and surgery in high-risk breast cancer patients.
  • PATIENTS AND METHODS: Ninety-seven women <60 years of age with breast cancer and extensive axillary lymph node involvement received three courses of FE120C (5-fluorouracil 500 mg/m2, epirubicin 120 mg/m2, cyclophosphamide 500 mg/m2) followed by surgery.
  • Eighty-one patients were randomized to receive either a fourth FE120C course alone or a fourth FE120C course followed by high-dose chemotherapy (cyclophosphamide 6 g/m2, thiotepa 480 mg/m2, carboplatin 1600 mg/m2).
  • Sixty patients relapsed after treatment.
  • In intention-to-treat analysis, the 5-year DFS rates were 47.5% in the conventional treatment arm and 49% in the high-dose arm, and the 5-year OS rates were 62.5% and 61%, respectively.
  • In the univariate analysis, the clinical T-stage before chemotherapy and the number of tumor-positive axillary lymph nodes after induction chemotherapy (P = 0.027) were significant prognostic factors for OS.
  • CONCLUSIONS: After a median follow-up of 6.9 years there was no difference in OS or DFS rates between the two treatment groups.
  • The number of tumor-positive axillary lymph nodes after induction chemotherapy and the clinical T-stage before chemotherapy were significant factors for OS.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2002 May;13(5):650-2 [12075732.001]
  • [CommentIn] Ann Oncol. 2003 Feb;14(2):341 [12562667.001]
  • (PMID = 12075736.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Reşorlu B, Türkölmez K, Ergün G, Baltacı S, Göğüş C, Bedük Y: The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node-positive bladder cancer. Int Urol Nephrol; 2010 Dec;42(4):959-64
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node-positive bladder cancer.
  • OBJECTIVE: To report the long-term follow up of patients with locally advanced bladder cancer treated with either adjuvant chemotherapy with gemcitabine/cisplatin (GC) or methotrexate, vinblastine, epirubicin, and cisplatin (MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival.
  • PATIENTS AND METHODS: Seventy-eight patients undergoing radical cystectomy for pathologic stage T3, T4 or lymph node-positive (N+) bladder cancer were divided to observation group (46 patients) and adjuvant chemotherapy group (32 patients).
  • RESULTS: One-, 2- and 5-year RFS rates were 74, 56.8 and 51.1% for chemotherapy arm, whereas these ratios were 50.6, 31 and 27.6% for control arm, respectively (P = 0.032).
  • RFS rates were significantly better in patients with lymph node-negative disease than in those with positive lymph nodes for control arm (P = 0.007), but for the chemotherapy arm there was no statistical difference between patients with lymph node-negative and -positive disease (P = 0.28).
  • Mean OS and RFS times were 31.03 and 28.4 months for chemotherapy arm, while they were 22.17 and 18.09 months for control arm, respectively (P = 0.142, P = 0.196).
  • On multivariate analysis, lymph node metastasis and adjuvant chemotherapy remained significant independent prognostic factors for cancer-specific survival.
  • CONCLUSIONS: Bladder cancer is chemosensitive, and using adjuvant chemotherapy is likely to improve the outcome of local treatment and to decrease the rates of distant metastases.
  • [MeSH-major] Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1992 Aug;148(2 Pt 1):302-6; discussion 306-7 [1635123.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Urol. 2005 Jul;174(1):14-20 [15947569.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201 [15939530.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1590-6 [3171626.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4963-74 [15939920.001]
  • [Cites] Curr Oncol Rep. 2005 May;7(3):207-14 [15847712.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v129-32 [16807440.001]
  • [Cites] Prog Clin Biol Res. 1989;303:533-40 [2675010.001]
  • [Cites] J Urol. 1996 Feb;155(2):495-9; discussion 499-500 [8558644.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1356-61 [18454792.001]
  • [Cites] Urology. 1996 Dec;48(6):868-75 [8973669.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):851-6 [10997813.001]
  • [Cites] Br J Urol. 1998 Sep;82(3):366-72 [9772872.001]
  • (PMID = 20405206.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • METHODS: Treatment was randomized between 6 cycles of cisplatin [C] (50 mg/m(2)) and doxorubicin [D] (45 mg/m(2)) with or without paclitaxel [P] (160 mg/m(2)).
  • RESULTS: Of 659 patients enrolled following surgery, 552 eligible patients were randomized to chemotherapy after irradiation.
  • Approximately 80% completed six cycles of chemotherapy.
  • Hematologic adverse events, sensory neuropathy and myalgia, were more frequent and severe in the paclitaxel arm (p<0.01) which was confirmed by Quality of Life assessments.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


8. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE: Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol; 2008 Dec;180(6):2384-8; discussion 2388
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer.
  • MATERIALS AND METHODS: Patients in arm I had clinical stage T2 with hydronephrosis or T3 bladder cancer.
  • They received 3 cycles of chemotherapy (200 mg/m(2) paclitaxel on day 1, AUC 5 carboplatin on day 1, and 800 mg/m(2) gemcitabine on days 1 and 8 of each 21-day cycle).
  • Patients in arm II with T4 or lymph node positive disease received up to 6 cycles of paclitaxel, carboplatin and gemcitabine.
  • RESULTS: In arm I, 31 patients were enrolled and 22 were evaluable for response.
  • In arm II, 37 patients were enrolled and 29 were evaluable for response with 24 suitable for surgical resection (83% of evaluable and 65% by intent to treat).
  • The most common toxicity was neutropenia with 39 events in arm I and 68 in arm II.
  • There were 7 deaths on study (5 during chemotherapy and 2 after cystectomy).
  • More studies of novel agents and combinations are needed to improve the efficacy and reduce the toxicity of neoadjuvant therapy for bladder cancer.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3018-24 [11408496.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):533-40 [10470696.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] Eur J Cancer. 2000 Jul;36 Suppl 2:17-25 [10908844.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):2993-8 [11753976.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2527-33 [11331332.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1927-34 [12801735.001]
  • (PMID = 18930256.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046592-209034; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / P30 CA046592-209034
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS109651; NLM/ PMC2716704
  •  go-up   go-down


9. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I: Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst; 2003 Apr 16;95(8):581-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.
  • We developed an aid called the "Decision Board" to help clinicians inform patients with lymph node-negative breast cancer of the risks and benefits of adjuvant chemotherapy.
  • We determined whether adding the Decision Board to the medical consultation improved patient knowledge and satisfaction compared with the medical consultation alone.
  • METHODS: Between October 1995 and March 2000, 176 women with lymph node-negative breast cancer who were candidates for adjuvant chemotherapy were randomly assigned to receive the Decision Board plus the medical consultation (83 patients) or the medical consultation alone (93 patients).
  • One week after the consultation, patients completed a questionnaire assessing their knowledge about breast cancer and chemotherapy.
  • Satisfaction with decision making was assessed 1 week and 3, 6, and 12 months after randomization, and differences between groups were analyzed by a repeated measures analysis of variance.
  • RESULTS: Patients in the Decision Board arm were better informed about breast cancer and adjuvant chemotherapy than patients in the control arm (mean knowledge score = 80.2 [on a scale of 0-100], 95% confidence interval [CI] = 77.1 to 83.3, and 71.7, 95% CI = 69.0 to 74.4, respectively; P<.001).
  • Over the entire study period, satisfaction with decision making was higher for patients in the Decision Board arm than for patients in the control arm (P =.032).
  • There was no statistically significant difference between the two groups in the number of patients who chose adjuvant chemotherapy (77% and 70% for patients in the Decision Board arm and those in the control arm, respectively; P =.303).
  • CONCLUSION: When making decisions regarding adjuvant chemotherapy, patients with early breast cancer who had been exposed to the Decision Board had better knowledge of the disease and treatment options and greater satisfaction with their decision making than those who received the standard consultation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / therapy. Decision Support Techniques. Patient Participation. Patient Satisfaction
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Decision Making. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local. Surveys and Questionnaires. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2003 Apr 16;95(8):570-1 [12697842.001]
  • (PMID = 12697850.001).
  • [ISSN] 0027-8874
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, Kato H: A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer; 2004 Feb;43(2):167-73
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).
  • The purpose of this study was to evaluate the efficacy of adjuvant chemotherapy with three courses of cisplatin and vindesine, in comparison to observation only, for N2 non-small cell lung cancer that had been completely resected.
  • Patients with pathologically demonstrated mediastinal lymph node metastasis (N2), who had undergone complete resection, were randomized to observation or adjuvant chemotherapy (cisplatin 80 mg/m2 on day 1; vindesine 3 mg/m2 on days 1 and 8: x3 courses).
  • A total of 119 patients were randomized (59 patients in the adjuvant arm and 60 with surgery alone).
  • Postoperative cisplatin with vindesine chemotherapy was not shown to be efficacious in cases of completely resected N2 non-small cell lung cancer in this setting of timing, dose and agents studied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14739037.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


14. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1062-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a prospective study of locally advanced noninflammatory breast cancer (LABC) after primary chemotherapy (CT) followed by external preoperative irradiation (RT).
  • METHODS AND MATERIALS: Between 1982 and 1998, 120 patients (75 Stage IIIA, 41 Stage IIIB, and 4 Stage IIIC according to AJCC staging system 2002) were treated by four courses of induction CT with anthracycline-containing combinations followed by preoperative RT (45 Gy to the breast and nodal areas) and a fifth course of CT.
  • After completion of local therapy, all patients received a sixth course of CT and a maintenance adjuvant CT regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumor), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumor bed; 32 had residual mass < or =3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.002).
  • In the nonconservative breast treatment group, of the 32 patients with no change in clinical tumor size after induction CT, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • Arm lymphedema was noted in 17% (14 of 81) after axillary dissection and in 2.5% (1 of 39) without axillary dissection.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumor response after induction CT and breast-conserving treatment combining preoperative RT and large wide excision.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234040.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


15. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S, Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group: Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol; 2003 Jun 15;21(12):2282-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
  • PURPOSE: To evaluate the survival benefit of adjuvant chemotherapy after curative resection in serosa-negative gastric cancer patients (excluding patients who were T1N0), we conducted a multicenter phase III clinical trial in which 13 cancer centers in Japan participated.
  • PATIENTS AND METHODS: From January 1993 to December 1994, 252 patients were enrolled into the study and allocated randomly to adjuvant chemotherapy or surgery alone.
  • The chemotherapy comprised intravenous mitomycin 1.33 mg/m2, fluorouracil (FU) 166.7 mg/m2, and cytarabine 13.3 mg/m2 twice weekly for the first 3 weeks after surgery, and oral FU 134 mg/m2 daily for the next 18 months for a total dose of 67 g/m2.
  • RESULTS: Ninety-eight percent of patients underwent gastrectomy with D2 or greater lymph node dissection.
  • There were no treatment-related deaths and few serious adverse events.
  • There was no significant difference in relapse-free and overall survival between the arms (5-year relapse-free survival 88.8% chemotherapy v 83.7% surgery alone; P =.14 and 5-year survival 91.2% chemotherapy v 86.1% surgery alone; P =.13, respectively).
  • Nine patients (7.1%) in the chemotherapy arm and 17 patients (13.8%) in the surgery-alone arm had cancer recurrence.
  • CONCLUSION: There was no statistically significant relapse-free or overall survival benefit with this adjuvant chemotherapy for patients with macroscopically serosa-negative gastric cancer after curative resection, and there was no statistical difference between the two arms relating to the types of cancer recurrence.
  • We do not recommend adjuvant chemotherapy with this regimen for this population in clinical practice.
  • [MeSH-major] Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Infusions, Intravenous. Japan. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Jun 15;21(12):2234-6 [12805321.001]
  • (PMID = 12805327.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M, Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst; 2003 Oct 1;95(19):1453-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
  • BACKGROUND: Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (NSCLC).
  • However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established.
  • METHODS: Between January 1994 and January 1999, 1209 patients with stage I, II, or IIIA NSCLC were randomly assigned to receive mitomycin C (8 mg/m2 on day 1), vindesine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on day 1) every 3 weeks for three cycles (MVP group; n = 606) or no treatment (control group; n = 603) after complete resection.
  • Randomization was stratified by investigational center, tumor size, lymph-node involvement, and the intention to perform radiotherapy.
  • The primary endpoint was overall survival and secondary endpoints were progression-free survival and toxicity associated with adjuvant treatment.
  • RESULTS: After a median follow-up time of 64.5 months, there was no statistically significant difference between the two patient groups in overall survival (hazard ratio = 0.96, 95% confidence interval = 0.81 to 1.13; P =.589) or progression-free survival (hazard ratio = 0.89, 95% confidence interval = 0.76 to 1.03; P =.128).
  • Grades 3 and 4 neutropenia occurred in 16% and 12%, respectively, of patients in the MVP arm.
  • Radiotherapy was completed by 65% of patients in the MVP arm and by 82% of patients in the control group.
  • CONCLUSION: This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC.
  • Given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Italy. Male. Middle Aged. Mitomycin / administration & dosage. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Patient Compliance. Patient Selection. Proportional Hazards Models. Prospective Studies. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage


17. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM: Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol; 2002 Apr 15;20(8):2053-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
  • Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm.
  • RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms.
  • Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis).
  • The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Melanoma / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Mitotic Index. Neoplasm Staging. Recombinant Proteins. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Survival Analysis. Ulcer

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956265.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA39229; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


18. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, Kwon KA, Lee S, Lee HS, Kim HJ: Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol; 2010 Dec;6(4):278-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
  • We evaluated the efficacy and toxicity of adjuvant chemoradiation versus chemotherapy in completely resected locally advanced gastric cancer.
  • METHODS: Patients with stage IIIA, IIIB and IV (without metastasis) gastric cancer were treated with chemoradiation and 5-fluorouracil/cisplatin (FP) (arm A) or FP (arm B).
  • Arm A consisted of one cycle of FP followed by 4500 cGY to radiation field with capecitabine.
  • Arm B consisted of six cycles of FP.
  • RESULTS: A total of 61 patients were enrolled, of whom 31 were placed in arm A and 30 in arm B.
  • We did not find any difference in 3-year disease-free survival between arm A and B (80.0 vs 75.2%, respectively; P = 0.887).
  • Seven patients (22.6%) relapsed in arm A and 12 patients (40%) relapsed in arm B.
  • Grade 3/4 neutropenia occurred in 48.5% of patients in arm A and 22.9% in arm B.
  • Grade 3 nausea or vomiting occurred in 6% in arm A and 14.6% in arm B.
  • CONCLUSION:   We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Liver Neoplasms / therapy. Lymph Node Excision. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Capecitabine. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • [CommentIn] Asia Pac J Clin Oncol. 2011 Jun;7(2):93-5 [21585687.001]
  • (PMID = 21114777.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Leong CN, Chung HT, Lee KM, Shakespeare TP, Mukherjee RK, Wong LC, Lu JJ, Tey J, Lim R, So JB, Back MF: Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer J; 2008 Jul-Aug;14(4):269-75
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
  • In INT-0116, 90% of patients had a limited or inadequate node dissection (D0 or D1).
  • Also, 17% of patients in the chemoradiation arm had to discontinue treatment because of toxicities.
  • The objectives of this retrospective study are to report the clinical outcomes of a cohort of patients who were mostly treated with a D2 node dissection and received adjuvant chemoradiation as per INT-0116, and the toxicities of chemoradiation in the context of more aggressive surgery.
  • Between March 1999 and November 2004, 70 consecutive patients with pathologic stage T3, T4, or node-positive disease were treated according to the chemoradiation arm of INT-0116.
  • Concurrent chemoradiation was given in cycle 2 and consisted of bolus 5-fluorouracil and leucovorin and radiotherapy (45 Gy over 25 fractions in 5 weeks).
  • Toxicities led to chemotherapy dose-reductions in 18 patients and dose-delay in 19 patients.
  • Including chemotherapy dose-reductions and delays, 66 patients (94%) completed the entire chemoradiation regimen.
  • CONCLUSION: In our cohort of 70 patients who had a more thorough D2 node dissection, adjuvant chemoradiation was well tolerated with acceptable toxicities and reasonable tumor control.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Gastrectomy. Lymph Node Excision. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome. Vitamin B Complex / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677137.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC): Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis Colon Rectum; 2006 Jul;49(7):982-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
  • PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.
  • The usefulness of adjuvant chemotherapy in a randomized, controlled trial by using these prognostic factors as stratification criteria was also investigated.
  • METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
  • Group W patients were assigned to Treatment Arm A (surgery alone) or Arm B (surgery, then 1-hexylcarbamoyl-5-fluorouracil); and Group U patients, to Treatment Arm C (same as B), and Arm D (surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C).
  • RESULTS: The Group W five-year survival rate was significantly superior to that in Group U (P = 0.0035).
  • There was a better survival rate in Treatment Arm A than Arm B (P = 0.0321), but no difference between Treatment Arms C and D.
  • CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
  • In such cases, it is possible for adjuvant chemotherapy to have a deleterious effect, and therefore, it is not recommended.
  • [MeSH-minor] Alkylating Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis / pathology. Mitomycin / administration & dosage. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625329.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Focan C, Beauduin M, Majois F, Canon JL, Cusumano G, Focan-Henrard D, Lobelle JP, Adjuvant Breast Cancer Project, Belgium: High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update. Clin Breast Cancer; 2004 Jun;5(2):136-41
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update.
  • One hundred ninety-four patients with histologically proven primary node-negative breast carcinoma were enrolled between December 1990 and October 1996, with 98 patients randomized into the tamoxifen arm and 96 into the MPA arm.
  • The relapse-free survival rate at 7 years in the tamoxifen arm was 93%, versus 81% in the MPA arm (P = 0.02).
  • The difference was observed in patients with stage T2 disease (100% in the tamoxifen group vs. 64% in the MPA group; P = 0.01), in younger and/or premenopausal patients (in patients < 50 years of age, 100% in the tamoxifen arm vs. 81% in the MPA arm [P = 0.02], and in patients > or = 50 years of age, 90% in the tamoxifen arm vs. 82% in the MPA arm [P = 0.16]).
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Medroxyprogesterone Acetate / administration & dosage. Tamoxifen / administration & dosage
  • [MeSH-minor] Age Factors. Aged. Analysis of Variance. Belgium. Biopsy, Needle. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Reference Values. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15245618.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


22. Galper S, Recht A, Silver B, Bernardo MV, Gelman R, Wong J, Schnitt SJ, Connolly JL, Harris JR: Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):125-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy.
  • PURPOSE: To estimate the possible efficacy of axillary radiation therapy (AXRT) following a positive sentinel node biopsy (SNB), we evaluated the risk of regional nodal failure (RNF) for patients with clinical Stage I or II, clinically node-negative invasive breast cancer treated with either no dissection or a limited dissection (LD) defined as removal of 5 nodes or less followed by AXRT.
  • The median dose to the axilla was 46 Gy.
  • The median dose to the supraclavicular fossa was 45 Gy.
  • Among patients found to have positive nodes on LD, adjuvant chemotherapy and tamoxifen were administered to 81% and 7% of subjects, respectively.
  • 4%) developed RNF as a first site of failure within 8 years.
  • Three of the 292 patients (1%) with no axillary dissection, none of 84 patients with pathologically negative nodes and 3 of 42 patients (7%) with pathologically involved nodes had RNF as a first site of failure.
  • Radiation pneumonitis developed in 5 patients (1.2%), brachial plexopathy in 5 (1.2%) and arm edema in 4 (1.2%).
  • CONCLUSION: These results imply that AXRT may be an effective and safe alternative to completion dissection for treatment of the axilla following a positive SNB.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Lymph Nodes / pathology. Lymphatic Irradiation
  • [MeSH-minor] Aged. Axilla. Biopsy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924981.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD: Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys; 2000 Jul 15;47(5):1191-200
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The usual sequence of multimodal treatment consisted of induction FAC or FACVP chemotherapy, mastectomy (if the tumor was operable), further chemotherapy, and radiation therapy to the chest wall and draining lymphatics.
  • Sixty-one patients treated from September 1977 to September 1985 received a maximal radiation dose of 60 Gy to the chest wall and 45-50 Gy to the regional lymph nodes, 22 treated once a day at 2 Gy per fraction, and 35 were treated b.i.d. (32 after mastectomy and all chemotherapy was completed, and 2 immediately after mastectomy; one patient had distant metastases discovered during b.i.d. irradiation, and treatment was stopped).
  • Based on the analysis of the failure patterns of the patients, the dose was increased for the b.i.d. patients in the new series, with 51 Gy delivered to the chest wall and regional nodes, followed by a 15-Gy boost to the chest wall with electrons.
  • From January 1986 to December 1993, 39 patients were treated b.i.d. to this higher dose after mastectomy and all the chemotherapy was completed; and 8 additional patients received preoperative irradiation with b.i.d. fractionation to 51 Gy.
  • During this period, another 7 patients were treated using standard daily doses of 2 Gy per fraction to a total of 60 Gy, either because they had a complete response or minimal residual disease at mastectomy or because their work schedule did not permit the b.i.d. regimen.
  • RESULTS: The median follow-up time was 5.7 years (range, 1.8-17.6 years).
  • To evaluate the effectiveness of dose escalation, a specific comparison of patients who received b.i.d. radiation after mastectomy and completion of adjuvant chemotherapy was performed.
  • There were 32 patients treated b.i.d. to 60 Gy in the old series versus 39 patients treated b.i.d. to 66 Gy in the new series.
  • Chemotherapy regimens did not change significantly during this time period.Long-term complications of radiation, such as arm edema more than 3 cm (7 patients), rib fracture (10 patients), severe chest wall fibrosis (4 patients), and symptomatic pneumonitis (5 patients), were comparable in the two groups, indicating that the dose escalation did not result in increased morbidity.
  • CONCLUSION: Twice-daily postmastectomy radiation to a total of 66 Gy for patients with inflammatory breast cancer resulted in improved locoregional control, disease free survival, and overall survival, and was well tolerated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Middle Aged. Neoplasm, Residual. Prednisone / administration & dosage. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Treatment Failure. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889372.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; VB0R961HZT / Prednisone; CAF protocol; CAFVP protocol
  •  go-up   go-down


24. Mencacci R, Alessandroni L, Arcangeli G, Bertolini R, Cecera A, Lopez M, Mardarella C, Parisi A, Tersigni R: [Ultraconservative treatment in stage I and II breast carcinoma. Results of a long-term follow-up on 500 operated breasts]. Minerva Chir; 2010 Aug;65(4):401-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultraconservative treatment in stage I and II breast carcinoma. Results of a long-term follow-up on 500 operated breasts].
  • Standard conservative approach includes surgical removal of the cancer with adequate cancer-free margins, axillary dissection, postoperative breast irradiation and adjuvant treatments when required.
  • The total postoperative radiation dosage was 50 Gy on the whole breast, associated with a boost of 10 Gy on tumor bed (20 Gy in T2 neoplasms).
  • Before 1997 node-positive patients were treated with axillary irradiation with 50 Gy.
  • Postoperative chemotherapy and/or hormonal therapy were administered to patients according with node-involvement, age and menopausal status.
  • RESULTS: In a postoperative setting, we observed 9% of axillary seromas or hematomas and 7% of oedema of the arm.
  • CONCLUSION: Recurrence and survival rates in breast-conserving surgery are consistent with indexed literature on conservative treatment of early breast cancer.
  • Women eligible for conservative treatment should be offered the choice of either wide tumorectomy or quadrantectomy with axillary lymph nodes removal and postoperative radiotherapy, or modified radical mastectomy.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Carcinoma / pathology. Carcinoma / therapy. Mastectomy, Segmental
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla / pathology. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hematoma / etiology. Humans. Lymph Node Excision / adverse effects. Lymphedema / etiology. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Seroma / etiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802429.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst; 2008 Jun 4;100(11):805-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting.
  • METHODS: After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P).
  • Associations and interactions were assessed with a multivariable Cox proportional hazards model for DFS for the following covariates: age, menopausal status, tumor size, lymph node status, type of chemotherapy, tumor size, positive lymph nodes, HER2 status, and hormone receptor status.
  • RESULTS: Among the 1246 eligible patients, estimated rates of DFS at 5 years were 78.5% in the FEC-P arm and 72.1% in the FEC arm (difference = 6.4%, 95% confidence interval [CI] = 1.6% to 11.2%; P = .006).
  • FEC-P treatment was associated with a 23% reduction in the risk of relapse compared with FEC treatment (146 relapses in the 614 patients in the FEC-P arm vs 193 relapses in the 632 patients in the FEC arm, hazard ratio [HR] = 0.77, 95% CI = 0.62 to 0.95; P = .022) and a 22% reduction in the risk of death (73 and 95 deaths, respectively, HR = 0.78, 95% CI = 0.57 to 1.06; P = .110).
  • Among the 928 patients for whom tumor samples were centrally analyzed, type of chemotherapy (FEC vs FEC-P) (P = .017), number of involved axillary lymph nodes (P < .001), tumor size (P = .020), hormone receptor status (P = .004), and HER2 status (P = .006) were all associated with DFS.
  • We found no statistically significant interaction between HER2 status and paclitaxel treatment or between hormone receptor status and paclitaxel treatment.
  • CONCLUSIONS: Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Cyclophosphamide / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infusions, Intravenous. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Andalusian Health Repository. Full Text from .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2008 Jun 4;100(11):761-3 [18505966.001]
  • (PMID = 18505968.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; FEC protocol
  • [Investigator] Martín M; López García-Asenjo JA; Rodríguez-Lescure A; Ruiz A; Almenar S; Alba E; Vicioso L; Calvo L; Guitián MD; Ruiz-Borrego M; Palacios J; Munárriz B; Vera F; Rodríguez CA; Crespo C; González-Palacios JF; Ramos M; de la Cruz A; Marco JM; Angulo JM; Lluch A; Ferrer J; Alvarez I; Ruiz I; Seguí MA; Sáez A; Mayordomo JI; Moros M; Antón A; Ríos MJ; Baena JM; Palomo MJ; Plazaola A; Rezola R; Modolell A; De las Heras P; Pelegrí A; Riu F; Mel JR; Alba J; Aranda E; Fuentes E; Adrover E; Peiró G; Alvarez JV; Puche JL; Aneiros J; Sánchez-Rovira P; Cueva C; Gonzalez S; López-Vega JM; Garijo MF
  •  go-up   go-down


26. Timmers PJ, Zwinderman AH, Coens C, Vergote I, Trimbos JB: Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer; 2010 Mar;46(5):880-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have analysed the data of a large randomised trial in early ovarian cancer in which detailed information of the surgical staging procedure was monitored.(5) METHODS: Data of the EORTC Adjuvant ChemoTherapy In Ovarian Neoplasm (ACTION) Trial were used in which 448 early ovarian cancer patients were randomised between postoperative chemotherapy in one arm and observation following surgery in the other.
  • RESULTS: Sampling of para-aortic nodes was omitted in 78% of the incompletely staged patients, while 52% of these patients had no pelvic lymph node dissection.
  • [MeSH-major] Neoplasm Staging / standards. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biopsy. Europe. Female. Humans. Lymph Nodes / surgery. Middle Aged. Multicenter Studies as Topic / methods. Prognosis. Randomized Controlled Trials as Topic / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [CommentIn] Eur J Cancer. 2010 Mar;46(5):856-8 [20163951.001]
  • (PMID = 20074933.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I, Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst; 2007 Apr 18;99(8):601-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
  • BACKGROUND: Promising findings obtained using a weekly regimen of 5-fluorouracil (5-FU), epidoxorubicin, leucovorin (LV), and cisplatin (PELFw) to treat locally advanced and metastatic gastric cancer prompted the Italian Group for the Study of Digestive Tract Cancer (GISCAD) to investigate the efficacy of this regimen as adjuvant treatment for high-risk radically resected gastric cancer patients.
  • METHODS: From January 1998 to January 2003, 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion (stage pT3 N0) and/or lymph node metastasis (stage pT2 or pT3 N1, N2, or N3), were enrolled in a trial of adjuvant chemotherapies; 201 patients were randomly assigned to receive the PELFw regimen, consisting of eight weekly administrations of cisplatin (40 mg/m2), LV (250 mg/m2), epidoxorubicin (35 mg/m2), 5-FU (500 mg/m2), and glutathione (1.5 g/m2) with the support of filgrastim, and 196 patients were assigned to a regimen consisting of six monthly administrations of a 5-day course of 5-FU (375 mg/m2 daily) and LV (20 mg/m2 daily, 5-FU/LV).
  • RESULTS: The 5-year survival rates were 52% in the PELFw arm and 50% in the 5-FU/LV arm.
  • Less than 10% of patients in either arm experienced a grade 3 or 4 toxic episode.
  • Neutropenia (occurring more often in the PELFw arm) and diarrhea and mucositis (more prevalent in the 5-FU/LV arm) were the most common serious side effects.
  • Nevertheless, only 19 patients (9.4%) completed the treatment in the PELFw arm and 85 (43%) patients completed the treatment in the 5-FU/LV arm.
  • CONCLUSIONS: Our study found no benefit from an intensive weekly chemotherapy in gastric cancer.
  • The extent of toxicity experienced by the patients in the adjuvant setting suggests that, in gastric cancer, chemotherapy may be more safely administered preoperatively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Sep 5;99(17):1345-6; author reply 1346-7 [17728219.001]
  • [CommentIn] J Natl Cancer Inst. 2007 Apr 18;99(8):580-2 [17440152.001]
  • (PMID = 17440161.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP protocol
  •  go-up   go-down


28. Helyer LK, Varnic M, Le LW, Leong W, McCready D: Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J; 2010 Jan-Feb;16(1):48-54
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphedema (LE) is a well-known postoperative complication after axillary node dissection (ALND).
  • Although, sentinel lymph node dissection (SLND) involves more focused surgery and less disruption of the axilla, early reports show up to 13% of patients experience some symptoms of LE.
  • The purpose of this study was to determine predictors of arm LE in our patients under going SLND with or without an ALND.
  • Prospective measurement of arm volume was carried every 6 months from date of diagnosis.
  • This data base was retrospectively reviewed for tumor stage, treatment, and subjective complaints of LE.
  • Objective LE was defined as a change greater than 200 mL compared with the control arm.
  • Arm volume changes were measured over 24 months (median follow-up 20 months) in 137 women: 82 stage I, 48 stage II, and 5 stage III; median age 56 years.
  • All patients underwent SLND for axillary staging and for 52 patients this was the only axillary staging procedure.
  • All node-positive patients (31) and 54 node-negative patients under went an immediate completion ALND, the latter as part of a study protocol.
  • Patient age, tumor size, number of nodes harvested, or adjuvant chemotherapy was not found to be predictive of LE by univariate analysis.
  • Univariate subgroup analysis compared the symptomatic to the nonsymptomatic patients and revealed the median number of nodes removed was higher in the symptomatic patients (17 verses 9, p = 0.045); however, these patients had a lower BMI (p = 0.0012).
  • The mean change in arm volume was not significantly different between the groups.
  • SLE occurs in one third of patients with objective arm swelling and most likely is multi-factorial in etiology.
  • [MeSH-major] Breast Neoplasms / surgery. Lymph Nodes / surgery. Lymphedema / etiology. Mastectomy / adverse effects. Obesity / epidemiology. Sentinel Lymph Node Biopsy / adverse effects
  • [MeSH-minor] Adult. Aged. Axilla. Body Mass Index. Cohort Studies. Confidence Intervals. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision / adverse effects. Lymph Node Excision / methods. Middle Aged. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Prospective Studies. Risk Assessment. Survival Analysis


29. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, Rossi RS, Chiari S, Campagnutta E, Greggi S, Angioli R, Manci N, Calcagno M, Scambia G, Fossati R, Floriani I, Torri V, Grassi R, Mangioni C: Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer; 2006 Sep 18;95(6):699-704
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was conducted to investigate the role of SL compared with lymph nodes sampling (CONTROL) in the management of early stage ovarian cancer.
  • Median operating time was longer and more patients required blood transfusions in the SL arm than the CONTROL arm (240 vs 150 min, P<0.001, and 36 vs 22%, P=0.012, respectively).
  • More patients in the SL group had positive nodes at histologic examination than patients on CONTROL (9 vs 22%, P=0.007).
  • Postoperative chemotherapy was delivered in 66% and 51% of patients with negative nodes on CONTROL and SL, respectively (P=0.03).
  • At a median follow-up of 87.8 months, the adjusted risks for progression (hazard ratio [HR]=0.72, 95%CI=0.46-1.21, P=0.16) and death (HR=0.85, 95%CI=0.49-1.47, P=0.56) were lower, but not statistically significant, in the SL than the CONTROL arm.
  • SL detects a higher proportion of patients with metastatic lymph nodes.
  • [MeSH-major] Lymph Node Excision. Ovarian Neoplasms / surgery. Pelvic Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1978 Jul;52(1):100-4 [683618.001]
  • [Cites] Cancer. 1977 Oct;40(4):1444-9 [561650.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(1):36-9 [3345782.001]
  • [Cites] Baillieres Clin Obstet Gynaecol. 1989 Mar;3(1):131-42 [2661087.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Gynecol Oncol. 1993 Apr;49(1):51-5 [8482561.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):150-4 [8276287.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2211-4 [11710876.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):113-25 [12529344.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):125-32 [12529345.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):467-72 [9190977.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):151-6 [9600823.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):560-6 [15840878.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):206s-210s [12743136.001]
  • [Cites] Gynecol Oncol. 1983 Aug;16(1):95-100 [6884834.001]
  • (PMID = 16940979.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360519
  •  go-up   go-down


30. Burcoş T, Popa E, Ivăşcanu A, Ardeleanu C, Zodieru I: [Merkel cell carcinoma]. Chirurgia (Bucur); 2001 Sep-Oct;96(5):509-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine dermal neoplasm.
  • This study is a retrospective outcomes analysis of two cases of MCC with data regarding clinical, histopathological, immunohistochemistry and also surgical, chimio and radiological treatment.
  • Diagnosis is best accomplished by a thorough clinical evaluation coupled with light microscopy and defined panel of immunohistochemical studies which are necessary for the definitive diagnosis of Merkel cell carcinoma (cytokeratins, neuron specific enoiase and chromogranin).
  • A lot of other disease must be included in the differential diagnosis.
  • Surgical excision of tumor and regional lymphadenectomy is the first step of treatment completed with radiotherapy and chemotherapy bat in advanced studies the rate of local or distant recidives is high.
  • [MeSH-minor] Aged. Arm. Axilla. Female. Humans. Lymph Node Excision / methods. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731194.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


31. Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A: A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer; 2004 Apr 1;100(7):1358-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Concurrent administration of chemotherapy and radiotherapy has the potential advantage of delaying neither treatment and providing radiation sensitization.
  • However, the optimal approach to concurrent treatment in women with early-stage breast carcinoma remains undefined.
  • METHODS: One hundred twelve women with AJCC Stage I or Stage II breast carcinoma with 0-3 positive axillary lymph nodes were enrolled in a prospective single-arm study of concurrent CMF and reduced-dose radiotherapy (39.6 gray [Gy] to the whole breast, 16-Gy boost).
  • There were no isolated regional lymph node recurrences.
  • One patient developed acute myelogenous leukemia.
  • An additional patient developed Grade 2 pneumonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Cyclophosphamide / therapeutic use. Fluorouracil / therapeutic use. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Radiation Dosage. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15042668.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


32. Cafiero F, Gipponi M, Lionetto R, P.A.R. Cooperative Study Group: Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report. J Surg Oncol; 2003 Jul;83(3):140-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: A randomised clinical trial was performed in patients undergoing radical surgery for rectal cancer to compare the efficacy and toxicity of adjuvant postoperative radiation therapy (RT) to sequential RT and chemotherapy (CT) with 5-fluorouracil (5-FU) plus levamisole (LEV).
  • The primary end point was overall survival (OS); secondary end points were disease-free survival (DFS), the rate of loco-regional recurrence, and treatment-related toxicity; the final results of this trial are reported.
  • METHODS: Patients in arm I underwent RT (50 Gy) in daily fractions of 2 Gy, 5 days/week for 5 weeks.
  • Patients in arm II began with 5-FU (450 mg/sqm/day intravenous (i.v.) bolus, days 1-5) plus LEV (150 mg/day orally, days 1-3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I.
  • The median follow-up time was 58.1 months (range: 1-3,271 days).
  • No significant difference was observed between the two arms of treatment as regards OS and DFS (P = 0.18 and P = 0.66, respectively).
  • Older age (>60 years) and pathologic lymph-node involvement defined the subgroups with the worst prognosis.
  • Cox regression analysis for DFS confirmed what was observed by univariate analysis for all variables: the only independent variable in predicting DFS was pathologic lymph-node involvement.
  • On the other hand, the similar efficacy of these two adjuvant modalities of treatment might be conditioned by both the low compliance (59%) to the CT regimen as well as the sequential, instead of concurrent, schedule of administration of RT and CT, which may have decreased further the expected efficacy of the combined regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Levamisole / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Care. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12827681.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Church JM, Gibbs P, Chao MW, Tjandra JJ: Optimizing the outcome for patients with rectal cancer. Dis Colon Rectum; 2003 Mar;46(3):389-402
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Historically, rectal cancer with transmural spread and/or lymph node involvement has presented a major challenge to surgeons, with a variable and often high risk of local recurrence and poor survival outcomes.
  • In recent years a large amount of literature has focused attention on the importance of surgical technique, tumor staging, and the optimal integration of CT and radiation therapy.
  • Although both radiation therapy and CT have a proven role in adjuvant therapy, the interpretation of many studies is confounded by unacceptably poor outcomes in the control arm, and in older studies the use of inferior chemotherapy and radiation therapy techniques.
  • Ongoing studies will better define the optimal combination and timing of chemotherapy and radiation therapy, with respect to both toxicity and survival endpoints.
  • [MeSH-major] Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy
  • [MeSH-minor] Colectomy / methods. Combined Modality Therapy. Endosonography. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Neoplasm Staging. Physical Examination / methods. Preoperative Care. Randomized Controlled Trials as Topic. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2003 Nov;46(11):1565
  • (PMID = 12626917.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 133
  •  go-up   go-down


34. Pocard M, Pouillart P, Asselain B, Salmon R: Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol; 2000 Mar;26(2):155-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, systemic treatments now allow control of tumour progression in certain cases.
  • We evaluated, in a group of highly selected patients with stabilization or complete response to systemic therapy, a particular management protocol for medically controlled BCLM: <<adjuvant>> liver surgery.
  • RESULTS: The mean number of cycles of chemotherapy, before surgery, was seven (3-24).
  • The 36-month survival rate differed according to the time to onset of BCLM: 45% before versus 82% after 48 months (P=0.023).
  • The RRL rate at 36 months differed according to the lymph node status of the initial breast cancer: 41% for N0-N1 versus 83% for N1b-N2 (P=0.021).
  • CONCLUSIONS: Adjuvant liver surgery allowed discontinuation of chemotherapy in 46% of cases and, in this highly selected patient group, allowed good quality prolonged survival.
  • It could be included in multicentre treatment protocols for controlled BCLM, one arm with prolonged chemotherapy, one with adjuvant liver surgery.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 10744935.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


35. Niloofar A, Mosalaei A, Shapour O, Mohammadianpanah M: Role of external irradiation in high-risk resected colon cancer. Indian J Cancer; 2005 Jul-Sep;42(3):133-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIM: The best therapeutic modality for colon cancer "one of the most common malignancies of human being" is surgical resection of primary tumor.
  • Adjuvant chemotherapy can help surgery to have a higher control and survival rate in high-risk resected patients, but the role of radiation therapy is the place of debate.
  • MATERIALS AND METHODS: This retrospective trial evaluated 65 eligible patients with surgically resected high-risk colon carcinoma (serosal and/or lymph node involvement), from May 1986 to February 2000.
  • The first group was treated with chemotherapy alone and the other with chemo-radiotherapy.
  • Chemotherapy included 5.FU 500 mg/m2sub/5days for 6-8 courses and radiotherapy consisted 45-55 Gy with 1.5-2 Gy/fraction.
  • RESULTS: Mean event-free survival was 140 and 101 months in chemotherapy and combined-therapy groups, respectively (P = 0.099).
  • Local recurrence rate was detected as 9.7% in the chemotherapy arm and 23.5% in the combined-therapy arm (P > 0.1).
  • Treatment-related morbidity and mortality has been significantly higher in the radiation arm (P < 0.001).
  • CONCLUSION: Postoperative external radiation as adjuvant treatment does not improve local control of the patients with colon carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / radiotherapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Care. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276013.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A, Intergruppo Italiano Linfomi (IIL): ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol; 2008 Apr;19(4):763-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients should be younger than 65 years with unfavorable stage IA and IIA HL (i.e. stage IA or IIA with bulky disease and/or subdiaphragmatic disease, erythrocyte sedimentation rate higher than 40, extranodal (E) involvement, hilar involvement and more than three involved lymph node areas).
  • RESULTS: Ninety-two patients were allocated to the ABVD arm and 89 to the EVE arm.
  • Complete remission (CR) rates at the end of treatment program [chemotherapy (CT) + RT] were 93% and 92% for ABVD and EVE arms, respectively (P = NS).
  • As a consequence of the different relapse rate, the 5-year failure-free survival (FFS) rate was significantly better for ABVD (90%) than for EVE (73%) arm (P < 0.05).
  • EVE CT, however, was significantly worse than ABVD in terms of RFS and FFS and cannot be recommended as initial treatment for HL.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180244.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


37. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D, Eastern Cooperative Oncology Group/Intergroup trial: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol; 2003 Apr 1;21(7):1214-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
  • PATIENTS AND METHODS: A total of 283 eligible patients with pT3-4a and/or node-positive disease were randomly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL (Wellferon, Burroughs-Wellcome, Research Park, NC) given daily for 5 days every 3 weeks for up to 12 cycles.
  • Patients remained on treatment until documented recurrence, excessive toxicity, or patient/physician preference deemed removal appropriate.
  • RESULTS: At median follow-up of 10.4 years, median survival was 7.4 years in the observation arm and 5.1 year in the treatment arm (log-rank P =.09).
  • Median recurrence-free survival was 3.0 years in the observation arm and 2.2 years in the interferon arm (P =.33).
  • A proportional hazards model examining the effects of treatment arm and time to recurrence on survival after recurrence among patients who recurred found that random assignment to interferon treatment (P =.009) and shorter time to recurrence (P <.0001) were independent predictors of shorter survival after recurrence.
  • Although no lethal toxicities were observed, severe (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxicities occurred in 11.4% of those randomly assigned to interferon treatment.
  • CONCLUSION: Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Interferon-alpha / therapeutic use. Kidney Neoplasms / therapy. Nephrectomy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Apr 1;21(7):1193-4 [12663704.001]
  • (PMID = 12663707.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23318
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


38. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM: Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg; 2004 Jul;26(1):202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Pancoast tumours.
  • Due to its localisation in the apex of the lung with invasion of the lower part of the brachial plexus, first ribs, vertebrae, subclavian vessels or stellate ganglion, a superior sulcus tumour causes characteristic symptoms, like arm or shoulder pain or Horner's syndrome.
  • Survival is better for T3 than T4 tumours and mediastinal lymph node involvement has been found to be a negative prognostic factor.
  • The management of superior sulcus tumours has evolved over the past 50 years.
  • Shaw and Paulson introduced combined modality treatment and for many years, this combination of radiotherapy and surgery was the treatment of choice with a mean 5-year survival of approximately 30%.
  • Also the addition of other chemotherapy agents or biologic agents such as angiogenesis inhibitors or tyrosine kinase inhibitors gives a new perspective in the treatment of Pancoast tumours.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201002.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


39. Yoshida T, Horiguchi J, Koibuchi Y, Kanoh T, Iijima K, Yoshida M, Kikuchi M, Takata D, Oyama T, Iino Y, Morishita Y: [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response]. Gan To Kagaku Ryoho; 2004 Jun;31(6):907-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After surgery, treatment of UFT and CPA was started.
  • Seven months after surgery, metastasis occurred at the left supraclavicular lymph node, and CPA, THP-adriamycine and 5-FU therapy was started.
  • Fourteen months after surgery, skin redness of the left upper arm, the left chest wall and contralateral breast, and a contralateral axillary lymph node swelling were recognized.
  • Neither docetaxel nor mitoxantrone-combined therapy was effective.
  • Trastuzumab therapy was started because of HER2 overexpression by immunohistochemistry, and partial response was received after 7 weeks.
  • Four months later, multiple nodules in the chest wall were recognized, and weekly treatment of trastuzumab and paclitaxel was started.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Middle Aged. Paclitaxel / administration & dosage. Receptor, ErbB-2 / biosynthesis. Remission Induction. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


40. Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM: Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol; 2010 May 10;28(14):2460-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
  • We evaluated the prognostic significance of autoantibodies in the European Organisation for Research and Treatment of Cancer 18991 trial, comparing long-term administration of pegylated IFN (PEG-IFN) with observation.
  • Prognostic impact of autoantibodies on recurrence-free survival (RFS) was assessed using the following three Cox models: a model that considered autoantibody appearance as a time-independent variable (model 1); a model that considered a patient to be autoantibody positive from the first positive test (model 2); and a model in which the most recent autoantibody test was used to define the status of the patient (model 3).
  • Occurrence of autoantibodies during follow-up was higher in the PEG-IFN-treated patients (18% in the observation arm v 52% in the PEG-IFN arm).
  • However, when guarantee-time bias was taken into account using model 2 (HR = 1.19; 95% CI, 0.75 to 1.88; P = .46) or method 3 (HR = 1.14; 95% CI, 0.71 to 1.83; P = .59), significance was lost.
  • Results were similar when treatment groups were analyzed separately.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Autoantibodies / blood. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Polyethylene Glycols / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Anticardiolipin / blood. Antibodies, Antinuclear / blood. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Kaplan-Meier Estimate. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Recombinant Proteins. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antinuclear; 0 / Antineoplastic Agents; 0 / Autoantibodies; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / anti-thyroglobulin; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


41. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1243-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
  • Eligible patients were those with bulky tumors (T2--T4) with or without pelvic lymph node involvement and without evidence of distant metastases.
  • They were randomized to receive goserelin, 3.6 mg every 4 weeks; and flutamide, 250 mg t.i.d. for 2 months before radiation therapy and during radiation therapy (Arm I), or radiation therapy alone (Arm II).
  • Of 471 randomized patients, 456 were evaluable: 226 on Arm I and 230 on Arm II.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Flutamide / therapeutic use. Goserelin / therapeutic use. Neoadjuvant Therapy. Prostatic Neoplasms / drug therapy. Radiotherapy, High-Energy
  • [MeSH-minor] Cause of Death. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Gonadotropin-Releasing Hormone / agonists. Humans. Life Tables. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483335.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21661; United States / NCI NIH HHS / CA / CA-32115
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide
  •  go-up   go-down


42. Kreis ME, Junginger T, Rödel C, Heinemann V, Nikolaou K, Mansmann U, Jauch KW: [The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI]. Zentralbl Chir; 2010 Aug;135(4):302-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI].
  • Multi-modal therapy further improves the rate of local recurrence in advanced rectal cancer.
  • In Germany neoadjuvant chemoradiation therapy is most frequently given for these tumours.
  • However, clinical staging by endosonography, CT scan and / or MRI is unreliable, particulary as regards lymph node category, which entails overtreatment of a relevant number of patients secondary to overstaging.
  • Thus, a subgroup of patients has to tolerate side effects and long-term sequelae of neoadjuvant therapy without having oncological benefit from this pretreatment.
  • In contrast to the T and N category, the latter may be predicted before treatment by pelvic MRI.
  • These patients are either operated without pretreatment (intervention arm) or receive neoadjuvant chemoradiation therapy with subsequent surgery (control arm).
  • If local recurrence in the intervention arm is not inferior to the control arm, this study may form the basis for an individualised therapeutic concept for rectal cancer based on preoperative MRI.
  • Potentially, chemoradiation therapy may be avoided in the future for patients who will have no oncological benefit from this treatment modality.
  • [MeSH-major] Magnetic Resonance Imaging. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy / adverse effects. Disease-Free Survival. Germany. Guideline Adherence. Humans. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Patient Selection. Postoperative Complications / etiology. Prognosis. Quality of Life. Rectum / pathology. Rectum / surgery. Reoperation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart ˙ New York.
  • [CommentIn] Zentralbl Chir. 2010 Aug;135(4):301 [20806130.001]
  • [ErratumIn] Zentralbl Chir. 2010 Aug;135(4):E1. Heinemanne, V [corrected to Heinemann, V]; Konstantin, N [corrected to Nikolaou, K]
  • [ErratumIn] Zentralbl Chir. 2010 Oct;135(5):485
  • (PMID = 20806131.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  •  go-up   go-down


43. Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE: Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):6056-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Fifty-eight patients with histologically confirmed relapsed B-cell NHL were randomized to receive concurrent treatment with rituximab and IL-12 (arm A) or rituximab with subsequent treatment with IL-12 after documented nonresponse or progression after rituximab (arm B).
  • Treatment consisted of 375 mg/m2 rituximab on days 1, 8, 15, and 22 and 300 ng/kg IL-12 given s.c. twice weekly starting on day 2 for arm A or upon progression for arm B.
  • RESULTS: The overall response rate was 37% (11 of 30) in arm A and 52% (13 of 25) in arm B.
  • All of the responses seen in arm B occurred while patients received rituximab, and no responses occurred during treatment with subsequent IL-12.
  • The median duration of response was 16 months for arm A and 12 months for arm B.
  • Biopsy specimens were serially obtained in a subset of patients and showed that changes in gene expression were different when cells from the peripheral blood were compared with cells from lymph node biopsies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Interleukin-12 / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Drug Administration Schedule. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Patient Selection. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Rituximab. T-Lymphocytes / immunology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA92104
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / RNA, Neoplasm; 187348-17-0 / Interleukin-12; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


44. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol; 2003 Nov 1;21(21):4016-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T-lymphocyte responses were assessed, by interferon gamma ELIspot assay (Chiron, Emeryville, CA), in peripheral-blood lymphocytes (PBLs) and in a lymph node draining a vaccine site (sentinel immunized node [SIN]).
  • The overall immune response was greater in the GM-CSF arm (P <.02).
  • Vitiligo developed in two of 13 patients in the GM-CSF arm but in no patients in the DC arm.
  • Helper T-cell responses to the tetanus peptide were detected in PBLs after vaccination and correlated with T-cell reactivity to the melanoma peptides.
  • Objective clinical responses were observed in two patients in the GM-CSF arm and one patient in the DC arm.
  • Stable disease was observed in two patients in the GM-CSF arm and one patient in the DC arm.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Mannitol / analogs & derivatives. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thoracic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dendritic Cells. Drug Administration Schedule. Female. Humans. Interleukin-2 / administration & dosage. Lymph Nodes / immunology. Male. Membrane Glycoproteins / administration & dosage. Middle Aged. Monophenol Monooxygenase / administration & dosage. Neoplasm Proteins / administration & dosage. Oleic Acids / administration & dosage. Peptide Fragments / administration & dosage. Survival Analysis. T-Lymphocytes / immunology. Treatment Outcome. gp100 Melanoma Antigen

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Sep 15;22(18):3834-5; author reply 3835 [15365084.001]
  • (PMID = 14581425.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00847; United States / NCI NIH HHS / CA / P30CA44579; United States / NCI NIH HHS / CA / R01 CA78519
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Oleic Acids; 0 / PMEL protein, human; 0 / Peptide Fragments; 0 / gp100 Melanoma Antigen; 0 / montanide ISA 51; 3OWL53L36A / Mannitol; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


45. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol; 2010 Oct 10;28(29):4485-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).
  • PATIENTS AND METHODS: This international, pivotal, single-arm, open-label, phase II study was conducted in patients with stage IB to IVA CTCL who had received one or more prior systemic therapies.
  • Response was determined by a composite assessment of total tumor burden including cutaneous disease, lymph node involvement, and blood (Sézary cells).
  • The median time to response was 2 months, and the median duration of response was 15 months.
  • Drug-related adverse events were generally mild and consisted mainly of GI disturbances and asthenic conditions.
  • CONCLUSION: Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL.
  • [MeSH-major] Depsipeptides / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin / drug effects. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Asthenia / chemically induced. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vomiting / chemically induced


46. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Wöltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M, German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN): Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer; 2005 Mar 14;92(5):843-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
  • In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0).
  • Two-, 5-, and 8-year survival rates were 81, 58, and 58% in the treatment arm, and 91, 76, and 66% in the observation arm (log rank P=0.0278), with a median follow-up of 4.3 years.
  • Two, 5-, and 8-year relapse-free survival rates were calculated at 54, 42, and 39% in the treatment arm, and at 62, 49, and 49% in the observation arm (log rank P=0.2398).
  • Stage-adapted subanalyses revealed no survival advantages of treatment over observation, as well.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Fluorouracil / therapeutic use. Germany. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Nephrectomy. Recombinant Proteins. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3442-50 [10999727.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):425-31 [11208835.001]
  • [Cites] Br J Cancer. 2001 Oct 19;85(8):1130-6 [11710825.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1214-22 [12663707.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):969-74 [12820332.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3133-40 [12810695.001]
  • [Cites] Lancet. 2004 Feb 21;363(9409):594-9 [14987883.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1188-94 [14981107.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1119-23 [1607917.001]
  • [Cites] JAMA. 1994 Mar 23-30;271(12):907-13 [8120958.001]
  • [Cites] World J Urol. 1995;13(3):174-7 [7550391.001]
  • [Cites] J Urol. 1996 Jan;155(1):19-25 [7490829.001]
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):156-61 [10199450.001]
  • (PMID = 15756254.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361915
  •  go-up   go-down






Advertisement